Latest From D-Pharm Ltd.
Samsung Bioepis is shifting gears moving into the development of novel biologics via a strategic collaboration with Takeda. The partners will initially focus on acute pancreatitis and jointly develop Takeda's preclinical candidate in the segment.
PwC anticipates a streamlining of the FDA approval process could address asset scarcity. AbbVie begins 2017 with three modest-sized deals, while PharmAthene and Altimmune join forces in a reverse-merger.
Hong Kong-listed Fosun Pharmaceutical plans to use new funds raised from super short-term commercial papers to back its subsidiary Jiangsu Wangban Pharmaceutical, and to add liquidity to its non-binding proposal to acquire Indian firm Gland. The group also says it has clear plans to reduce debts to obtain a higher investment rating.
As the third quarter earnings season starts to trail off, investors could be forgiven for wondering what it takes anymore for the share prices of companies to go up, rather than down. Over the past two weeks, the delineation between big pharmaceutical companies and big biotechnology companies couldn't have been clearer with big biotechs like Amgen, Gilead, Celgene and Biogen reporting better than expected quarterly profits and raising guidance, whereas big pharmas like Pfizer, Lilly, GlaxoSmithKline and Bristol Myers Squibb all drifted in the shadow of their respective patent expiries (scripintelligence.com, 25 October 2012).
- Drug Discovery Tools
- Therapeutic Areas
- Neurology, Nervous System
- Middle East
- Parent & Subsidiaries
- D-Pharm Ltd.
- Senior Management
Alex Kozak, PhD, Pres. & CEO
Gilad Rosenberg, MD, VP, Clin. Dev.
Ofra Yamin, VP, Fin. & Human Resources
- Contact Info
Phone: (972) 8-9385100
Kiryat Weizmann Sci. Park
P.O. Box 2313 Rehovot, 76123
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.